These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 27782226)

  • 1. [The evolution of the treatment of advanced NSCLC.].
    Morabito A
    Recenti Prog Med; 2016 Oct; 107(10):510-514. PubMed ID: 27782226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the 'panacea' for all patients?
    Morabito A
    BMC Med; 2018 Feb; 16(1):24. PubMed ID: 29448944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Therapies for Lung Cancer.
    Stinchcombe TE
    Cancer Treat Res; 2016; 170():165-82. PubMed ID: 27535394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety of second-line treatment options for non-small cell lung cancer.
    Rossi A; Maione P; Santabarbara G; Sacco PC; Casaluce F; Sgambato A; Barzelloni ML; Palazzolo G; Gridelli C
    Expert Opin Drug Saf; 2017 Apr; 16(4):471-479. PubMed ID: 28276858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Nivolumab in second-line treatment of squamous non-small cell lung cancer.].
    De Marinis F; Passaro A
    Recenti Prog Med; 2016 Dec; 107(12):634-640. PubMed ID: 27997006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung.
    Goss GD; Spaans JN
    Oncologist; 2016 Feb; 21(2):205-13. PubMed ID: 26768483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
    Ellis PM; Vella ET; Ung YC
    Clin Lung Cancer; 2017 Sep; 18(5):444-459.e1. PubMed ID: 28416123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALK inhibitors and advanced non-small cell lung cancer (review).
    Rossi A; Maione P; Sacco PC; Sgambato A; Casaluce F; Ferrara ML; Palazzolo G; Ciardiello F; Gridelli C
    Int J Oncol; 2014 Aug; 45(2):499-508. PubMed ID: 24889366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Impact of histology on efficacy of pemetrexed: pemetrexed in second-line setting and as maintenance therapy after first-line treatment in Chinese patients with advanced NSCLC].
    Zhou C; Wu Y; Sun Y; Wang Y; Wang X; Zhang X
    Zhonghua Zhong Liu Za Zhi; 2014 Jan; 36(1):29-33. PubMed ID: 24685083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial.
    Hanna NH; Kaiser R; Sullivan RN; Aren OR; Ahn MJ; Tiangco B; Voccia I; Pawel JV; Kovcin V; Agulnik J; Gaschler-Markefski B; Barrueco J; Sikken P; Schloss C; Kim JH;
    Lung Cancer; 2016 Dec; 102():65-73. PubMed ID: 27987591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New perspectives in the second-line treatment of non squamous NSCLC patients: Results from a large Italian Lung Cancer Working Group.
    Cortinovis D; Gregorc V; Migliorino MR; Abate MI; Manzo A; Malapelle U; Morabito A;
    Crit Rev Oncol Hematol; 2017 Jan; 109():35-41. PubMed ID: 28010896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC).
    Ding L; Liu K; Jiang Z; Chen Q; Zhou N; Liang Y; Gao H; Hong X; Wu H
    Tumour Biol; 2015 Apr; 36(4):2491-9. PubMed ID: 25417899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer.
    Wakelee H; Zvirbule Z; De Braud F; Kingsley CD; Mekhail T; Lowe T; Schütte W; Lena H; Lawler W; Braiteh F; Cosgriff T; Kaen D; Boyer M; Hsu J; Phan S; Novello S
    Clin Lung Cancer; 2017 Jan; 18(1):50-59. PubMed ID: 27856142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis.
    Créquit P; Chaimani A; Yavchitz A; Attiche N; Cadranel J; Trinquart L; Ravaud P
    BMC Med; 2017 Oct; 15(1):193. PubMed ID: 29082855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel agents in second-line therapy for EGFR wild-type Advanced Non-Small-Cell Lung Cancer.
    El Amarti L; Elghissassi I; Layachi M; Mrabti H; Errihani H
    Gulf J Oncolog; 2016 May; 1(21):84-8. PubMed ID: 27250896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extending survival of stage IV non-small cell lung cancer.
    Carnio S; Novello S; Mele T; Levra MG; Scagliotti GV
    Semin Oncol; 2014 Feb; 41(1):69-92. PubMed ID: 24565582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer.
    Liang Y; Wakelee HA; Neal JW
    Clin Lung Cancer; 2015 Sep; 16(5):366-73. PubMed ID: 25665893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.
    Lee JO; Kim TM; Lee SH; Kim DW; Kim S; Jeon YK; Chung DH; Kim WH; Kim YT; Yang SC; Kim YW; Heo DS; Bang YJ
    J Thorac Oncol; 2011 Sep; 6(9):1474-80. PubMed ID: 21642865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer.
    Klein R; Wielage R; Muehlenbein C; Liepa AM; Babineaux S; Lawson A; Schwartzberg L
    J Thorac Oncol; 2010 Aug; 5(8):1263-72. PubMed ID: 20581708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platinum-Vinorelbine Induction Chemotherapy plus Bevacizumab With and Without Pemetrexed Switch Maintenance in Advanced NSCLC.
    Michelsen L; Sørensen JB
    Anticancer Res; 2015 Nov; 35(11):6255-9. PubMed ID: 26504059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.